There were 1,594 press releases posted in the last 24 hours and 413,117 in the last 365 days.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NVDA, AGN, DXC and ALKS

NEW YORK, Jan. 22, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.        

NVIDIA Corporation (NASDAQGS: NVDA)
Class Period: August 10, 2017 to November 15, 2018
Lead Plaintiff Deadline: February 19, 2019

The lawsuit alleges that NVIDIA Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) NVIDIA’s growth in its gaming GPU revenue was driven, as repeatedly denied by Defendants, in significant part by the spiked demand for those GPUs among cryptocurrency miners; (ii) NVIDIA did not have, as Defendants asserted, visibility into its inventory channel; (iii) NVIDIA was unable to adapt to the volatility of cryptocurrency markets; (iv) as cryptocurrency prices dropped, NVIDIA hid halting growth from cryptocurrency miners by continuing to push mid-range GPUs into the channel; (v) this would foreseeably cause an oversupply of gaming card inventory levels on the market and ultimately lead to over three months of excess inventory in NVIDIA’s channel; and (vi) as a result, NVIDIA’s public statements were materially false and misleading at all relevant times.

Get additional information about the NVDA lawsuit: http://www.kleinstocklaw.com/pslra-1/nvidia-corporation-loss-submission-form?wire=3

Allergan plc (NYSE: AGN)
Class Period: May 9, 2017 to December 19, 2018
Lead Plaintiff Deadline: February 19, 2019

During the Class Period, and unbeknownst to investors, Allergan misled investors regarding various “pharma and device approvals” and concealed the fact that the Company’s CE Mark for its textured breast implants and tissue expanders was expiring in Europe.    On December 19, 2018, the Company announced that, following a compulsory recall request from Agence Nationale de Sécurité du Médicament (“ANSM”), the French regulatory authority, the Company had suspended the sale of these products and that it was withdrawing all remaining supplies from European markets. The suspension of sales stemmed directly from the expiration of the company's CE Mark for these products, and the stock price fell drastically following the news.

Get additional information about the AGN lawsuit: http://www.kleinstocklaw.com/pslra-1/allergan-plc-loss-submission-form?wire=3

DXC Technology Company (NYSE: DXC)
Class Period: February 8, 2018 to November 6, 2018
Lead Plaintiff Deadline: February 25, 2019

The complaint alleges DXC Technology Company made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had changed or planned to change the operations of its sales teams, deploying generalized sales teams as opposed to the specialized teams that were better capable of delivering specialized services to its clients; (b) the Company’s workforce optimization strategy of sharply reducing staff while reducing costs was resulting in a shortage of sales personnel who could execute on demand for services, thereby risking and ultimately losing sales and revenue opportunities; (c) in light of the above, the Company’s revenue and financial performance guidance for the fiscal year 2019 and its reaffirmation of the guidance during the Class Period was without a reasonable basis.

Get additional information about the DXC lawsuit: http://www.kleinstocklaw.com/pslra-1/dxc-technology-company-loss-submission-form?wire=3

Alkermes plc (NASDAQGS: ALKS)
Class Period: February 17, 2017 to November 1, 2018
Lead Plaintiff Deadline: February 25, 2019

The lawsuit alleges Alkermes plc made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) the FDA had advised Alkermes to follow a certain protocol in connection with its New Drug Application submission for its drug ALKS 5461; (2) Alkermes had failed to follow that protocol; (3) consequently, an FDA advisory committee voted 21 to 2 against the approval of ALKS 5461; and (4) as a result, Alkermes’ public statements were materially false and/or misleading at all relevant times.

Get additional information about the ALKS lawsuit: http://www.kleinstocklaw.com/pslra-1/alkermes-plc-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com 

Klein NEW logo black transparent.png